METTL3 's role in cervical cancer development through m 6 A modification
The FASEB Journal · 2024
DOI: 10.1096/fj.202400580 ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2024. Verfasst von Yuqiu Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Gynecology Laboratory, Medical Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medical Sciences, Ji…. Hauptthemen laut MEDLINE: Adenosine, Cell Proliferation, Methyltransferases, Uterine Cervical Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: |Natural Science Foundation of Shandong Province (), Natural Science Foundation of Shandong Province.
Abstract (Originalsprache)
N6‐methylated adenosine (m 6 A) is a crucial RNA modification in eukaryotes, particularly in cancer. However, its role in cervical cancer (CC) is unclear. We aimed to elucidate the part of m 6 A in CC by analyzing methyltransferase‐like 3 (METTL3) expression, identifying downstream targets, and exploring the underlying mechanism. We assessed METTL3 expression in CC using western blotting, quantitative polymerase chain reaction (qPCR), and immunohistochemistry. In vitro and in vivo experiments examined METTL3's role in CC. We employed RNA sequencing, methylated RNA immunoprecipitation sequencing, qPCR, and RNA immunoprecipitation qPCR to explore METTL3's mechanism in CC. METTL3 expression was upregulated in CC, promoting cell proliferation and metastasis. METTL3 knockdown inhibited human cervical cancer by inactivating AKT/mTOR signaling pathway. METTL3‐mediated m 6 A modification was observed in CC cells, targeting phosphodiesterase 3A (PDE3A). METTL3 catalyzed m 6 A modification on PDE3A mRNA through YTH domain family protein 3 (YTHDF3). Our study indicated the mechanism of m 6 A modification in CC and suggested the METTL3/YTHDF3/PDE3A axis as a potential clinical target for CC treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gynecology Laboratory, Medical Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong, P.R. China.
- Gynecology Laboratory, Shandong Provincial Hospital, Jinan, Shandong, P.R. China.
- JiNan Key Laboratory of Diagnosis and Treatment of Major Gynecological Disease, Jinan, Shandong, P.R. China.
- Department of Obstetrics and Gynecology, Peking University Shenzhen Hospital, Shenzhen, Guangdong, P.R. China.
- Department of Gynecology, Lingcheng District's Traditional Chinese Medicine Hospital, Dezhou, Shandong, P.R. China.
- Department of Gynecology, The Fourth People's Hospital of Ji'nan, Jinan, Shandong, P.R. China.
ORCID-Profile: Yuqiu Liu, Changzhong Li, Qianqian Deng, Xingye Ren, Hongqing Wang
Förderung
- |Natural Science Foundation of Shandong Province ()
- Natural Science Foundation of Shandong Province
Zitieren
APA
Liu, Y., Li, C., Deng, Q., Ren, X., & Wang, H. (2024). METTL3 's role in cervical cancer development through m 6 A modification. The FASEB Journal. https://doi.org/10.1096/fj.202400580
Vancouver
Liu Y, Li C, Deng Q, Ren X, Wang H. METTL3 's role in cervical cancer development through m 6 A modification. The FASEB Journal. 2024. doi:10.1096/fj.202400580
BibTeX
@article{Liu2024,
author = {Liu, Yuqiu and Li, Changzhong and Deng, Qianqian and Ren, Xingye and Wang, Hongqing},
title = {METTL3 's role in cervical cancer development through m 6 A modification},
journal = {The FASEB Journal},
year = {2024},
doi = {10.1096/fj.202400580}
}
EUVIMED